Specifically, Naringenin-7-O-β-D-glucoside induces dose-dependent cytotoxicity in MDA-MB-231 triple-negative breast cancer cells, accompanied by increased DNA fragmentation and reduced expression of the epidermal growth factor receptor (EGFR), suggesting interference with tumor progression pathways [44]. Here, EGFR is linked to triple-negative breast carcinoma.